The PE Ratio as of December 2024 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is -5.56

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.56. This represents a change of 21.07% compared to the average of -4.59 of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical PE Ratio (quarterly & annually)

How has ACRS PE Ratio performed in the past?

The mean historical PE Ratio of Aclaris Therapeutics, Inc. over the last ten years is -7.14. The current -5.56 PE Ratio has changed 7.69% with respect to the historical average. Over the past ten years (40 quarters), ACRS's PE Ratio was at its highest in in the September 2019 quarter at -0.20. The PE Ratio was at its lowest in in the December 2015 quarter at -25.48.

Aclaris Therapeutics, Inc. (ACRS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aclaris Therapeutics, Inc. (ACRS) Average PE Ratio

How has ACRS PE Ratio performed in the past?

The current PE Ratio of Aclaris Therapeutics, Inc. (ACRS) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Aclaris Therapeutics, Inc. (ACRS) PE Ratio vs. Peers

How is ACRS’s PE Ratio compared to its peers?

Aclaris Therapeutics, Inc.’s PE Ratio is greater than Neogen Corporation (-111.60), less than Qiagen N.V. (107.22), greater than Olink Holding AB (publ) (-96.25), less than Syneos Health, Inc. (16.61), less than Sotera Health Company (53.33), less than RadNet, Inc. (401.14), greater than Myriad Genetics, Inc. (-10.70), less than Genetron Holdings Limited (0), less than Biodesix, Inc. (-4.91), less than Castle Biosciences, Inc. (125.93), less than Prenetics Global Limited (-1.47), less than IQVIA Holdings Inc. (25.81), less than Medpace Holdings, Inc. (28.79), less than ICON Public Limited Company (23.26),

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.